Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.
2.

Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men.

Zlotta AR, Kuk C.

Eur Urol. 2019 Apr;75(4):562-563. doi: 10.1016/j.eururo.2018.12.038. Epub 2019 Jan 12. No abstract available.

PMID:
30642612
3.

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.

J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.

4.

Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.

Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg J, Toi A, Shiah YJ, Fraser M, van der Kwast T, Bristow RG, Bapat B, Diamandis EP, Boutros PC, Zlotta AR.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw258.

PMID:
28376164
5.

Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy.

Boström PJ, Thoms J, Sykes J, Ahmed O, Evans A, van Rhijn BW, Mirtti T, Stakhovskyi O, Laato M, Margel D, Pintilie M, Kuk C, Milosevic M, Zlotta AR, Bristow RG.

Bladder Cancer. 2016 Jan 7;2(1):101-109.

6.

Anthrax Toxin Receptor 1 Is Essential for Arteriogenesis in a Mouse Model of Hindlimb Ischemia.

Andersen NJ, Boguslawski EA, Naidu AS, Szot C, Bromberg-White JL, Kits K, Kuk CY, Holton LE, St Croix B, Chambers CM, Duesbery NS.

PLoS One. 2016 Jan 19;11(1):e0146586. doi: 10.1371/journal.pone.0146586. eCollection 2016.

7.

Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series.

Siadat F, Sykes J, Zlotta AR, Aldaoud N, Egawa S, Pushkar D, Kuk C, Bristow RG, Montironi R, van der Kwast T.

Prostate. 2015 Sep;75(12):1277-84. doi: 10.1002/pros.23009. Epub 2015 May 11.

PMID:
25963383
8.

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts.

Andersen NJ, Boguslawski EB, Kuk CY, Chambers CM, Duesbery NS.

Int J Oncol. 2015 Jul;47(1):71-80. doi: 10.3892/ijo.2015.2989. Epub 2015 May 6.

9.

Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer.

Liu Y, Noon AP, Aguiar Cabeza E, Shen J, Kuk C, Ilczynski C, Ni R, Sukhu B, Chan K, Barbosa-Morais NL, Hermanns T, Blencowe BJ, Azad A, van der Kwast TH, Catto JW, Zlotta AR, Wrana JL.

Eur Urol. 2014 Dec;66(6):982-6. doi: 10.1016/j.eururo.2014.07.045. Epub 2014 Sep 6.

PMID:
25199720
10.

Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men.

Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Lockwood G, Sykes J, Kwast Tv.

Eur Urol. 2014 Oct;66(4):619-22. doi: 10.1016/j.eururo.2014.06.026. Epub 2014 Jul 8.

PMID:
25012523
11.

Positive surgical margins: race or surgeon?

Zlotta AR, Kuk C.

Eur Urol. 2015 Mar;67(3):458-9. doi: 10.1016/j.eururo.2014.05.036. Epub 2014 Jun 17. No abstract available.

PMID:
24951361
12.
13.

The importance of surgeon characteristics on impacting oncologic outcomes for patients undergoing radical cystectomy.

Bhindi B, Yu J, Kuk C, Sridhar SS, Hamilton RJ, Finelli A, Jewett MA, Evans A, Fleshner NE, Zlotta AR, Kulkarni GS.

J Urol. 2014 Sep;192(3):714-9. doi: 10.1016/j.juro.2014.02.093. Epub 2014 Mar 1.

PMID:
24594406
14.

Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.

Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Sykes J, Lockwood G, van der Kwast TH.

J Natl Cancer Inst. 2013 Jul 17;105(14):1050-8. doi: 10.1093/jnci/djt151. Epub 2013 Jul 11.

PMID:
23847245
15.

Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.

Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, Shariat SF, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR.

Eur Urol. 2013 Feb;63(2):379-85. doi: 10.1016/j.eururo.2012.07.047. Epub 2012 Aug 2.

PMID:
22883484
16.

Platelet-adenovirus vs. inert particles interaction: effect on aggregation and the role of platelet membrane receptors.

Gupalo E, Kuk C, Qadura M, Buriachkovskaia L, Othman M.

Platelets. 2013;24(5):383-91. doi: 10.3109/09537104.2012.703792. Epub 2012 Jul 19.

PMID:
22812520
17.

Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols.

Perlis N, Turker P, Bostrom PJ, Kuk C, Mirtti T, Kulkarni G, Fleshner NE, Jewett MA, Finelli A, Zlotta AR.

World J Urol. 2013 Feb;31(1):161-7. doi: 10.1007/s00345-012-0905-2. Epub 2012 Jul 19.

PMID:
22810052
18.

Does patient age affect survival after radical cystectomy?

Horovitz D, Turker P, Bostrom PJ, Mirtti T, Nurmi M, Kuk C, Kulkarni G, Fleshner NE, Finelli A, Jewett MA, Zlotta AR.

BJU Int. 2012 Dec;110(11 Pt B):E486-93. doi: 10.1111/j.1464-410X.2012.11180.x. Epub 2012 May 2.

19.

Calcium sensitivity of α-actinin is required for equatorial actin assembly during cytokinesis.

Jayadev R, Kuk CY, Low SH, Murata-Hori M.

Cell Cycle. 2012 May 15;11(10):1929-37. doi: 10.4161/cc.20277. Epub 2012 May 15.

PMID:
22544326
20.

Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.

Turker P, Bostrom PJ, Wroclawski ML, van Rhijn B, Kortekangas H, Kuk C, Mirtti T, Fleshner NE, Jewett MA, Finelli A, Kwast TV, Evans A, Sweet J, Laato M, Zlotta AR.

BJU Int. 2012 Sep;110(6):804-11. doi: 10.1111/j.1464-410X.2012.10939.x. Epub 2012 Feb 9.

21.

Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer.

Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, Lotan Y, Shariat SF, Nortier J.

Eur Urol. 2011 Jun;59(6):1026-31. doi: 10.1016/j.eururo.2011.03.027. Epub 2011 Apr 1.

PMID:
21458152
22.

Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.

Kakiashvili DM, van Rhijn BW, Trottier G, Jewett MA, Fleshner NE, Finelli A, Azuero J, Bangma CH, Vajpeyi R, Alkhateeb S, Hanna S, Kostynsky A, Kuk C, Van Der Kwast TH, Zlotta AR.

BJU Int. 2011 Feb;107(4):540-6. doi: 10.1111/j.1464-410X.2010.09572.x. Epub 2010 Sep 7.

23.

Optimal timing of radical cystectomy in T1 high-grade bladder cancer.

Boström PJ, Alkhateeb S, van Rhijn BW, Kuk C, Zlotta AR.

Expert Rev Anticancer Ther. 2010 Dec;10(12):1891-902. doi: 10.1586/era.10.183.

PMID:
21110756
24.

Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study.

Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR.

BJU Int. 2011 Jul;108(1):24-30. doi: 10.1111/j.1464-410X.2010.09834.x. Epub 2010 Nov 10.

25.

Role of surgery in high-risk localized prostate cancer.

Lawrentschuk N, Trottier G, Kuk C, Zlotta AR.

Curr Oncol. 2010 Sep;17 Suppl 2:S25-32.

26.

Nidogen-2: a new serum biomarker for ovarian cancer.

Kuk C, Gunawardana CG, Soosaipillai A, Kobayashi H, Li L, Zheng Y, Diamandis EP.

Clin Biochem. 2010 Mar;43(4-5):355-61. doi: 10.1016/j.clinbiochem.2009.10.012. Epub 2009 Oct 31.

27.

Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer.

Gunawardana CG, Kuk C, Smith CR, Batruch I, Soosaipillai A, Diamandis EP.

J Proteome Res. 2009 Oct;8(10):4705-13. doi: 10.1021/pr900411g.

PMID:
19663500
28.

Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP.

Mol Cell Proteomics. 2009 Apr;8(4):661-9. doi: 10.1074/mcp.M800313-MCP200. Epub 2008 Dec 1.

29.

Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients.

Komatsu N, Saijoh K, Kuk C, Liu AC, Khan S, Shirasaki F, Takehara K, Diamandis EP.

Exp Dermatol. 2007 Jun;16(6):513-9.

PMID:
17518992
30.

Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy.

Komatsu N, Saijoh K, Kuk C, Shirasaki F, Takehara K, Diamandis EP.

Br J Dermatol. 2007 May;156(5):875-83.

PMID:
17459012
31.

[Cloning and analysis of structural organization of Hox genes in the Polychaete Nereis virens].

Andreeva TF, Kuk Ch, Korchagina NM, C'ikc'm M, Dondya AK.

Ontogenez. 2001 May-Jun;32(3):225-33. Russian.

PMID:
11548412
32.

Lactic acid dehydrogenase isoenzyme in periodically amputated rat incisor pulp.

Bae CK, Soon KD, Kuk CH.

Taehan Chikkwa Uisa Hyophoe Chi. 1972 Jan;10(1):15-21. No abstract available.

PMID:
4505516

Supplemental Content

Support Center